PDCD1LG2 and ovarian cancer: In fact, a study on ovarian cancer reported that blocking both PD-L1 and PD-L2 could help to overcome resistance to ICI treatment by unleashing the immune responses, thus indicating a clear role of both ligands in immune regulation (68).